COMMUNIQUÉS West-GlobeNewswire
-
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
18/02/2026 -
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
18/02/2026 -
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
18/02/2026 -
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
18/02/2026 -
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
18/02/2026 -
BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
18/02/2026 -
Medline announces participation in the Barclays 28th Annual Global Healthcare Conference
18/02/2026 -
Medicenna Therapeutics Announces Participation in Upcoming Conferences
18/02/2026 -
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
18/02/2026 -
NervGen Pharma to Participate at Upcoming Investor Conferences
18/02/2026 -
Constant Therapy Health Joins American Heart Association Innovators’ Network to Advance AI‑Driven Neurorehabilitation
18/02/2026 -
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
18/02/2026 -
Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Year U.S. Brewing and Commercial Partnership
18/02/2026 -
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
18/02/2026 -
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
18/02/2026 -
EyePoint Appoints Michael Campbell as Chief Commercial Officer
18/02/2026 -
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
18/02/2026 -
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
18/02/2026 -
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
18/02/2026
Pages